Literature DB >> 3163230

Significance of multiparameter flow cytometric analysis of ovarian cancer.

W C Fowler1, M B Maddock, D H Moore, S Haskill.   

Abstract

A prospective flow cytometric examination of ovarian epithelial tumors was undertaken to further characterize aneuploid (including triploid and tetraploid) tumor cell populations according to expression of ovarian tumor antigen CA125 and to expression of class I (normally present in ovarian epithelium) and class II (normally absent in ovarian epithelium) major histocompatibility complex antigens. Samples from thirty-two of 42 patients (76%) exhibited at least one aneuploid population of tumor cells. Separate analysis of the aneuploid and diploid components of samples with aneuploid populations revealed between-tumor variation: seven of 23 aneuploid populations (30%) were positive for CA125; eight of 22 aneuploid populations (40%) exhibited substantial decreases in major histocompatibility complex class I expression, compared with corresponding diploid components of the same samples; and eight of 22 aneuploid populations (36%) exhibited substantial expression of major histocompatibility complex class II antigens. The frequencies of aneuploid populations and of the foregoing antigen expression categories were independent of tumor cell type, stage, and grade. The significance of these results for prognosis remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3163230     DOI: 10.1016/0002-9378(88)90081-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

1.  Tissue preparation for simultaneous flow cytometric quantitation of tumour associated antigens and DNA in solid tumours.

Authors:  P A van Dam; J V Watson; D G Lowe; H Cox; M Curling; J H Shepherd
Journal:  J Clin Pathol       Date:  1990-10       Impact factor: 3.411

2.  Tumour cell activity markers in epithelial ovarian cancer: are biochemical and cytometric indices complementary?

Authors:  C W Redman; C Finn; K Ward; K Kelly; E J Buxton; R Varma; W Shortland-Webb; D M Luesley
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.